🇺🇸 depot medroxyprogesterone acetate in United States

13 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Drug Interaction — 3 reports (23.08%)
  2. Blood Hiv Rna Increased — 2 reports (15.38%)
  3. Abnormal Sleep-Related Event — 1 report (7.69%)
  4. Anaemia — 1 report (7.69%)
  5. Blood Glucose Decreased — 1 report (7.69%)
  6. Dizziness — 1 report (7.69%)
  7. Dry Skin — 1 report (7.69%)
  8. Enuresis — 1 report (7.69%)
  9. Fibromyalgia — 1 report (7.69%)
  10. Hypoaesthesia — 1 report (7.69%)

Source database →

depot medroxyprogesterone acetate in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is depot medroxyprogesterone acetate approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for depot medroxyprogesterone acetate in United States?

University of Sao Paulo is the originator. The local marketing authorisation holder may differ — check the official source linked above.